Pharmacological relevance of endoxifen in a laboratory simulation of breast cancer in postmenopausal patients

Journal of the National Cancer Institute

Volumn 106, Issue 10, 2014, Pages

  Maximov, Philipp Y ^a   McDaniel, Russell E ^a   Fernandes, Daphne J ^a   Bhatta, Puspanjali ^a   Korostyshevskiy, Valeriy R ^a   Curpan, Ramona F ^b   Jordan, V Craig ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b ACADEMY OF ROMANIAN SCIENTISTS   (Romania)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; ENDOXIFEN; ESTRADIOL; ESTRONE; TAMOXIFEN; 4-HYDROXY-N-DESMETHYLTAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; DRUG DERIVATIVE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL PROLIFERATION; CELL PROLIFERATION ASSAY; CONTROLLED STUDY; DISEASE SIMULATION; ESTRADIOL BLOOD LEVEL; ESTRONE BLOOD LEVEL; FEMALE; GENE EXPRESSION; GENOTYPE; HUMAN; HUMAN CELL; IN VITRO STUDY; LABORATORY; MCF 7 CELL LINE; POSTMENOPAUSE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; AGED; BREAST TUMOR; CHEMISTRY; DRUG EFFECT; GENE EXPRESSION REGULATION; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY; TUMOR CELL LINE;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOCHROME P-450 CYP2D6; ESTRADIOL; ESTROGEN RECEPTOR MODULATORS; ESTRONE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MCF-7 CELLS; MIDDLE AGED; POSTMENOPAUSE; REAL-TIME POLYMERASE CHAIN REACTION; RESEARCH DESIGN; TAMOXIFEN;

EID: 84985019814     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju283     Document Type: Article

References (60)

1. Jordan VC. Tamoxifen: a most unlikely pioneering medicine. Nat Rev Drug Discov. 2003;2(3):205-213.
2. Jordan VC. Tamoxifen: catalyst for the change to targeted therapy. Eur J Cancer. 2008;44(1):30-38.
3. EBCTCG. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351(9114):1451-1467.
4. Davies C, Godwin J, Gray R, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patientlevel meta-Analysis of randomised trials. Lancet. 2011;378(9793):771-784.
5. EBCTCG. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687-1717.
6. Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381(9869):805-816.
7. Berry DA, Inoue L, Shen Y, et al. Modeling the impact of treatment and screening on U.S. breast cancer mortality: a Bayesian approach. J Natl Cancer Inst Monogr. 2006;(36):30-36.
8. Jordan VC, Collins MM, Rowsby L, et al. A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J Endocrinol. 1977;75(2):305-316.
9. Jordan VC, Dix CJ, Naylor KE, et al. Nonsteroidal antiestrogens: their biological effects and potential mechanisms of action. J Toxicol Environ Health. 1978;4(2-3):363-390.
10. Allen KE, Clark ER, Jordan VC. Evidence for the metabolic activation of non-steroidal antioestrogens: a study of structure-Activity relationships. Br J Pharmacol. 1980;71(1):83-91.
11. Lieberman ME, Jordan VC, Fritsch M, et al. Direct and reversible inhibition of estradiol-stimulated prolactin synthesis by antiestrogens in vitro. J Biol Chem. 1983;258(8):4734-4740.
12. Furr BJ, Jordan VC. The pharmacology and clinical uses of tamoxifen. Pharmacol Ther. 1984;25(2):127-205.
13. Mauvais-Javis P, Baudot N, Castaigne D, et al. trans-4-Hydroxytamoxifen concentration and metabolism after local percutaneous administration to human breast. Cancer Res. 1986;46(3):1521-1525.
14. Lien EA, Solheim E, Kvinnsland S, et al. Identification of 4-hydroxy-Ndesmethyltamoxifen as a metabolite of tamoxifen in human bile. Cancer Res. 1988;48(8):2304-2308.
15. Lien EA, Solheim E, Lea OA, et al. Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment. Cancer Res. 1989;49(8):2175-2183.
16. Stearns V, Johnson MD, Rae JM, et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst. 2003;95(23):1758-1764.
17. Jin Y, Desta Z, Stearns V, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst. 2005;97(1):30-39.
18. Schroth W, Goetz MP, Hamann U, et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA. 2009;302(13):1429-1436.
19. Lammers LA, Mathijssen RH, van Gelder T, et al. The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer. Br J Cancer. 2010;103(6):765-771.
20. Madlensky L, Natarajan L, Tchu S, et al. Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin Pharmacol Ther. 2011;89(5):718-725.
21. Lash TL, Cronin-Fenton D, Ahern TP, et al. CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark. J Natl Cancer Inst. 2011;103(6):489-500.
22. Regan MM, Leyland-Jones B, Bouzyk M, et al. CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial. J Natl Cancer Inst. 2012;104(6):441-451.
23. Rae JM, Drury S, Hayes DF, et al. CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients. J Natl Cancer Inst. 2012;104(6):452-460.
24. Zanger UM, Fischer J, Raimundo S, et al. Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics. 2001;11(7):573-585.
25. Jordan VC, Obiorah I, Fan P, et al. The St. Gallen Prize Lecture 2011: evolution of long-term adjuvant anti-hormone therapy: consequences and opportunities. Breast. 2011;20 Suppl 3:S1-11.
26. Jordan VC, Fritz NF, Tormey DC. Endocrine effects of adjuvant chemotherapy and long-term tamoxifen administration on node-positive patients with breast cancer. Cancer Res. 1987;47(2):624-630.
27. Ravdin PM, Fritz NF, Tormey DC, et al. Endocrine status of premenopausal node-positive breast cancer patients following adjuvant chemotherapy and long-term tamoxifen. Cancer Res. 1988;48(4):1026-1029.
28. Murdter TE, Schroth W, Bacchus-Gerybadze L, et al. Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Clin Pharmacol Ther. 2011;89(5):708-717.
29. Balaburski GM, Dardes RC, Johnson M, et al. Raloxifene-stimulated experimental breast cancer with the paradoxical actions of estrogen to promote or prevent tumor growth: a unifying concept in anti-hormone resistance. Int J Oncol. 2010;37(2):387-398.
30. Maximov P, Sengupta S, Lewis-Wambi JS, et al. The Conformation of the Estrogen Receptor Directs Estrogen-Induced Apoptosis in Breast Cancer: A Hypothesis. Horm Mol Biol Clin Investig. 2011;5(1):27-34.
31. Sweeney EE, McDaniel RE, Maximov PY, et al. Models and Mechanisms of Acquired Antihormone Resistance in Breast Cancer: Significant Clinical Progress Despite Limitations. Horm Mol Biol Clin Investig. 2012;9(2):143-163.
32. Sengupta S, Sharma CG, Jordan VC. Estrogen regulation of X-box binding protein-1 and its role in estrogen induced growth of breast and endometrial cancer cells. Horm Mol Biol Clin Investig. 2010;2(2):235-243.
33. Berman HM, Westbrook J, Feng Z, et al. The Protein Data Bank. Nucleic Acids Res. 2000;28(1):235-242.
34. Shiau AK, Barstad D, Loria PM, et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell. 1998;95(7):927-937.
35. Friesner RA, Banks JL, Murphy RB, et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem. 2004;47(7):1739-1749.
36. Halgren TA, Murphy RB, Friesner RA, et al. Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem. 2004;47(7):1750-1759.
37. Cauley JA, Gutai JP, Kuller LH, et al. The epidemiology of serum sex hormones in postmenopausal women. Am J Epidemiol. 1989;129(6):1120-1131.
38. Hankinson SE, Willett WC, Manson JE, et al. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 1998;90(17):1292-1299.
39. Cummings SR, Duong T, Kenyon E, et al. Serum estradiol level and risk of breast cancer during treatment with raloxifene. JAMA. 2002;287(2):216-220.
40. Rae JM, Johnson MD, Scheys JO, et al. GREB 1 is a critical regulator of hormone dependent breast cancer growth. Breast Cancer Res Treat. 2005;92(2):141-149.
41. Maximov PY, McDaniel RE, Fernandes DJ, et al. Simulation with cells in vitro of tamoxifen treatment in premenopausal breast cancer patients with different CYP2D6 genotypes. Br J Pharmacol. 2014; In press.
42. Lonard DM, Nawaz Z, Smith CL, et al. The 26S proteasome is required for estrogen receptor-Alpha and coactivator turnover and for efficient estrogen receptor-Alpha transactivation. Mol Cell. 2000;5(6):939-948.
43. Wijayaratne AL, McDonnell DP. The human estrogen receptor-Alpha is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators. J Biol Chem. 2001;276(38):35684-35692.
44. Wu X, Hawse JR, Subramaniam M, et al. The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells. Cancer Res. 2009;69(5):1722-1727.
45. Johnson MD, Zuo H, Lee KH, et al. Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat. 2004;85(2):151-159.
46. Levenson AS, Jordan VC. The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (aspartate) in the estrogen receptor. Cancer Res. 1998;58(9):1872-1875.
47. Lewis-Wambi JS, Kim H, Curpan R, et al. The selective estrogen receptor modulator bazedoxifene inhibits hormone-independent breast cancer cell growth and down-regulates estrogen receptor alpha and cyclin D1. Mol Pharmacol. 2011;80(4):610-620.
48. Pike AC, Brzozowski AM, Walton J, et al. Structural insights into the mode of action of a pure antiestrogen. Structure. 2001;9(2):145-153.
49. Wu X, Subramaniam M, Grygo SB, et al. Estrogen receptor-beta sensitizes breast cancer cells to the anti-estrogenic actions of endoxifen. Breast Cancer Res. 2011;13(2):R27.
50. Roger P, Sahla ME, Makela S, et al. Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res. 2001;61(6):2537-2541.
51. Iwao K, Miyoshi Y, Egawa C, et al. Quantitative analysis of estrogen receptor-Alpha and-beta messenger RNA expression in breast carcinoma by real-time polymerase chain reaction. Cancer. 2000;89:1732-1738.
52. Shaaban AM, O'Neill PA, Davies MP, et al. Declining estrogen receptorbeta expression defines malignant progression of human breast neoplasia. Am J Surg Pathol. 2003;27:1502-1512.
53. Horwitz KB, Koseki Y, McGuire WL. Estrogen control of progesterone receptor in human breast cancer: role of estradiol and antiestrogen. Endocrinology. 1978;103:1742-1751.
54. May FE, Johnson MD, Wiseman LR, et al. Regulation of progesterone receptor mRNA by oestradiol and antioestrogens in breast cancer cell lines. J Steroid Biochem. 1989;33:1035-1041.
55. Hawse JR, Subramaniam M, Cicek M, et al. Endoxifen's molecular mechanisms of action are concentration dependent and different than that of other anti-estrogens. PLoS One. 2013;8:e54613.
56. Jordan VC. Biochemical pharmacology of antiestrogen action. Pharmacol Rev. 1984;36:245-276.
57. Fan P, Agboke FA, McDaniel RE, et al. Inhibition of c-Src blocks oestrogen-induced apoptosis and restores oestrogen-stimulated growth in long-term oestrogen-deprived breast cancer cells. Eur J Cancer. 2014;50:457-468.
58. Yao K, Lee ES, Bentrem DJ, et al. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice. Clin Cancer Res. 2000;6:2028-2036.
59. Jordan VC. Linking estrogen-induced apoptosis with decreases in mortality following long-term adjuvant tamoxifen therapy. J Natl Cancer Inst. 2014; In press.
60. Brauch H, Schwab M. Prediction of tamoxifen outcome by genetic variation of CYP2D6 in post-menopausal women with early breast cancer. Br J Clin Pharmacol. 2014;77:695-703.